logo-loader
Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals chief executive Paul Rennie buys more shares

Paradigm is focused on repurposing the drug pentosan polysulfate sodium in its injectable form

Paul rennie
A number of clinical trial results are due over the next year

Paradigm Biopharmaceuticals Ltd (ASX:PAR) chief executive officer and managing director Paul Rennie has purchased 780,392 shares since November 15, 2017 for a total consideration of $545,000.

Rennie made the purchases through Paradigm’s share placements in 2017 and 2018 and via the company’s employee share plan.

Rennie’s latest purchase today (December 13, 2018) has increased his total holding (direct and indirect) in Paradigm to 23,379,935 shares.

READ: Paradigm Biopharmaceuticals gains on market with upcoming clinical trial read-out, wider treatment potential

Paradigm is focused on repurposing the drug pentosan polysulfate sodium in its injectable form (iPPS), a US FDA approved drug that has a long track record of safely treating inflammation.

The biotech company is working on several clinical indications for orthopaedic treatment of OA, BMEL, Ross River virus and Chikungunya and plans to establish commercial partnerships with multiple leading pharmaceutical companies.

A number of clinical trial results are due over the next year, including the phase-2b OA trial due by the end of December.

Paradigm’s drug repurposing strategy will deliver key benefits including lower costs; accelerated development timelines; and higher success rates than the standard clinical development timeline.

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: $1.44

Market: ASX
Market Cap: $276.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read